Status:
COMPLETED
Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapprov...
Eligibility Criteria
Inclusion
- Blood glucose criteria must be met
- On a stable dose of insulin as defined by the protocol
- Body mass inde (BMI) in the range 22-45
Exclusion
- Type 1 diabetes
- Pregnancy or lactation
- Evidence of serious diabetic complications
- Evidence of serious cardiovascular complications
- Laboratory value abnormalities as defined by the protocol
- Other protocol defined exclusion criteria may apply
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
254 Patients enrolled
Trial Details
Trial ID
NCT00099931
Start Date
May 1 2004
End Date
June 1 2005
Last Update
May 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Investigative Sites, Germany